Patients with multiple myeloma face significantly higher risks of severe complications from SARS-CoV-2 infections. Consequently, monitoring Multiple Myeloma COVID-19 outcomes has become essential for developing effective pandemic preparedness strategies. The ASH Research Collaborative recently launched the COSMIC study to provide a proof of concept for a decentralized monitoring network. This innovative approach simplifies data collection while ensuring robust participation from diverse patient populations across varied clinical sites.

The Decentralized Study Framework

The COSMIC study utilized a site-based provider network to facilitate rapid patient recruitment. Specifically, clinicians at eight participating sites shared best practices monthly to accelerate execution. Patients provided consent and navigated the study through an electronic portal. This portal allowed them to share electronic health record data and complete patient-reported outcomes at multiple intervals. Notably, participants received compensation for their time, which likely contributed to the high engagement levels observed throughout the six-month study period.

Tracking Multiple Myeloma COVID-19 Outcomes through Rapid Accrual

During the four-month accrual period, the study successfully consented 201 patients. These participants represented a wide age range from 30 to 93 years, with a median age of 67. Furthermore, the cohort was demographically diverse, including 17% non-Hispanic Black and 8% Hispanic/Latino participants. This diversity is crucial for understanding Multiple Myeloma COVID-19 outcomes across different populations. The study achieved remarkable data completion rates, starting at 97% at baseline and remaining high at 79% after six months. Consequently, researchers could track infections and vaccinations with high precision.

Key Findings on Vaccination and Quality of Life

At the start of the study, over half of the patients reported a history of COVID-19. Most had already received a median of four vaccinations. During the observation period, the group recorded 18 additional infections and 57 more vaccine doses. Importantly, there were no significant changes in health-related quality of life (HRQOL) over time, regardless of infection history. This suggests that while the risk remains, current management strategies help maintain stability for these patients. Overall, COSMIC proves that decentralized evidence generation can effectively address evolving medical needs in real-time.

FAQs

How did the COSMIC study collect patient data?

The study used a decentralized electronic portal where patients provided consent and completed surveys. Clinicians at participating sites facilitated recruitment and patients could optionally link their electronic health records for more comprehensive monitoring.

Did COVID-19 infection impact the quality of life in myeloma patients?

According to the COSMIC study results, there were no significant differences in health-related quality of life (HRQOL) scores over time between patients with or without a history of COVID-19 infection.

Why is decentralized monitoring important for myeloma patients?

Decentralized monitoring allows for rapid patient accrual and real-world data collection without requiring frequent in-person visits. This is particularly beneficial for immunocompromised patients who may need to minimize exposure to clinical environments during a pandemic.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or establish a doctor-patient relationship. Patients should consult their healthcare providers for personalized medical decisions. Refer to the latest local and national guidelines for clinical practice.

References

Wood WA et al. Feasibility of Decentralized Real-World Monitoring of SARS-CoV-2 Booster Vaccines and COVID-19 Outcomes in Myeloma. Blood Adv. 2026 Feb 24. doi: undefined. PMID: 41734388.

ClinicalTrials.gov. COVID19 OutcomeS in Myeloma and the Impact of VaCcines (COSMIC). NCT05831787.

Wood WA et al. Initial Results from the ASH Research Collaborative's COSMIC: A Decentralized, Real-World Evidence Study for Patients with Multiple Myeloma. ResearchGate. 2025.